Abstract
A pro-tumorigenic role for adipocytes has been identified in breast cancer, and reliance on fatty acid catabolism found in aggressive tumors. The molecular mechanisms by which tumor cells coopt neighboring adipocytes, however, remain incompletely understood. Here, we describe a direct interaction linking tumorigenesis to adjacent adipocytes. We examine breast tumors and their normal adjacent tissue from several patient cohorts, patient-derived xenografts, and mouse models, and find that lipolysis and lipolytic signaling are activated in neighboring adipose tissue. We find that functional gap junctions form between breast cancer cells and adipocytes. As a result, cAMP is transferred from breast cancer cells to adipocytes and activates lipolysis in a gap junction-dependent manner. We find that connexin 31 (GJB3) promotes receptor triple negative breast cancer growth and activation of lipolysis in vivo. Thus, direct tumor cell-adipocyte interaction contributes to tumorigenesis and may serve as a new therapeutic target in breast cancer.
Introduction
Aggressive breast cancers, particularly Triple-Negative Breast Cancer (TNBC), are metabolically demanding and often rely on fatty acid oxidation to sustain rapid growth. While previous research has highlighted the role of paracrine signaling—where tumors secrete cytokines to stimulate lipolysis in distant fat cells—the direct physical interactions at the tumor-adipocyte interface have remained elusive. This study investigates the hypothesis that cancer cells establish a direct, "hardwired" connection with neighboring adipocytes to efficiently extract metabolic resources.
Methods
The researchers employed a multi-disciplinary approach to map the tumor-adipocyte interface:
- Clinical Imaging (3CB): Radiographic imaging of 46 patients to quantify water, lipid, and protein content in tissue surrounding invasive tumors.
- Proteomics and Microdissection: Laser capture microdissection (LCM) followed by LC-MS/MS proteomics on normal adjacent tissue (NAT) from 75 patients.
- Functional Connectivity: Dye-transfer assays using calcein and fluorescent cAMP analogues to track direct molecular movement between cell types.
- Genetic Models: CRISPR/Cas9 and shRNA targeting of GJB3 (Connexin 31) in TNBC cell lines, validated in patient-derived xenografts (PDX) and transgenic mouse models.
Results
Metabolic Reprogramming of the Normal Adjacent Tissue
Clinical imaging and histological analysis revealed that the adipose tissue immediately adjacent to the tumor (within 2mm) undergoes significant metabolic reprogramming. There is a stepwise decrease in lipid content and a corresponding reduction in adipocyte area as one moves from the periphery (R3) toward the tumor lesion (R1).
Gap Junction-Mediated cAMP Transfer and Lipolysis
The study identified Connexin 31 (Cx31/GJB3) as the primary protein forming functional gap junctions between TNBC cells and adipocytes. These junctions facilitate the direct transfer of cAMP from tumor cells—which maintain high internal concentrations—into neighboring fat cells. This influx of cAMP triggers lipolysis, as evidenced by increased levels of phosphorylated HSL (pHSL) and HNF4α in the NAT.
Cx31 is Required for Tumor Progression
In vivo validation showed that depleting Cx31 significantly delayed tumor onset and reduced growth rates. In one mouse model experiment, 0 out of 10 mice transplanted with Cx31-depleted cells developed tumors within 180 days, compared to 100% of control mice within 50 days. Functional assays confirmed that dye transfer between TNBC cells and adipocytes was reduced by 30-60% upon Cx31 depletion. The growth defect could be rescued by pharmacological activation of lipolysis in the surrounding adipose tissue using the drug CL316243, confirming that the primary function of the Cx31 gap junction is to secure a metabolic supply line for the tumor.
Discussion
This research identifies a novel mechanism of metabolic parasitism in breast cancer. By forming direct gap junctions with adipocytes, tumor cells bypass the inefficiencies of paracrine signaling to directly activate lipolysis and fuel their growth. While Cx31 represents a promising therapeutic target, its role in normal physiology poses a challenge for drug development. Future efforts must focus on disrupting this specific tumor-stroma interface to starve aggressive cancers of their lipid fuel.
Summary updated